Tags

Type your tag names separated by a space and hit enter

[Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
Clin Calcium. 2012 Oct; 22(10):1557-66.CC

Abstract

Hyperphosphatemia is the most common complication among patients with chronic kidney disease. Large scale observational studies have identified hyperphosphatemia as an independent risk factor for cardiovascular disease and mortality in hemodialysis patients. The combination therapy of dietary phosphate restriction and phosphate removal with dialysis treatment is still not enough to achieve the serum phosphate within the target. Thererfore, phosphate binders is necessary for many dialyzed patients with hyperphosphatemia. In this article, we will review the detail and development of phosphate binders and recommendation for clinical practice in hyperphosphatemia.

Authors+Show Affiliations

Division of Nephrology, Department of Internal Medicine, Wakayama Medical University, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

23023637

Citation

Negi, Shigeo, et al. "[Newly Development of Phosphate Binders in Hyperphosphatemic Patients With Kidney Dysfunction]." Clinical Calcium, vol. 22, no. 10, 2012, pp. 1557-66.
Negi S, Yamanaka S, Koreeda D, et al. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction]. Clin Calcium. 2012;22(10):1557-66.
Negi, S., Yamanaka, S., Koreeda, D., Yashiro, M., & Shigematsu, T. (2012). [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction]. Clinical Calcium, 22(10), 1557-66.
Negi S, et al. [Newly Development of Phosphate Binders in Hyperphosphatemic Patients With Kidney Dysfunction]. Clin Calcium. 2012;22(10):1557-66. PubMed PMID: 23023637.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction]. AU - Negi,Shigeo, AU - Yamanaka,Shintaro, AU - Koreeda,Daisuke, AU - Yashiro,Mitsuru, AU - Shigematsu,Takashi, PY - 2012/10/2/entrez PY - 2012/10/2/pubmed PY - 2013/3/21/medline SP - 1557 EP - 66 JF - Clinical calcium JO - Clin Calcium VL - 22 IS - 10 N2 - Hyperphosphatemia is the most common complication among patients with chronic kidney disease. Large scale observational studies have identified hyperphosphatemia as an independent risk factor for cardiovascular disease and mortality in hemodialysis patients. The combination therapy of dietary phosphate restriction and phosphate removal with dialysis treatment is still not enough to achieve the serum phosphate within the target. Thererfore, phosphate binders is necessary for many dialyzed patients with hyperphosphatemia. In this article, we will review the detail and development of phosphate binders and recommendation for clinical practice in hyperphosphatemia. SN - 0917-5857 UR - https://www.unboundmedicine.com/medline/citation/23023637/[Newly_development_of_phosphate_binders_in_hyperphosphatemic_patients_with_kidney_dysfunction]_ L2 - https://medlineplus.gov/chronickidneydisease.html DB - PRIME DP - Unbound Medicine ER -